15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Practical introduction of novel oral anticoagulants through an anticoagulation nurse. The Leeuwarden model

      brief-report

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction

          This paper describes the implementation of novel oral anticoagulants (NOACs) through an anticoagulation nurse. Logistics and tasks of this new function are described and preliminary data are presented.

          Methods

          Indications for NOACs are explained by the treating cardiologists. Thereafter, the patient is referred to the anticoagulation nurse before starting a NOAC. After providing a patient with information and checking the creatinine clearance, co-medication and medical history, a prescription for NOAC is made.

          Results

          In 3 months, 51 patients were referred for NOAC therapy. Mean age was 68 years, CHA2DS2-VASc score was 2.9. Renal function was impaired in 28 %. Only 63 % of the patients had an uneventful start-up. NOAC therapy was withheld or prematurely stopped in 22 %. 30 % of patients needed a reduced NOAC dose. In 37 %, the anticoagulation nurse had extended patient contact, mainly because of (presumed) side effects.

          Conclusion

          Given the number of interactions that were made using a separate patient contact through the anticoagulation nurse, this seems to be an important improvement in the quality of care and deserves further expansion.

          Related collections

          Most cited references4

          • Record: found
          • Abstract: not found
          • Article: not found

          Bleeding risk with dabigatran in the frail elderly.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial

            Vernakalant is a novel, relatively atrial-selective antiarrhythmic agent for conversion of atrial fibrillation (AF) to sinus rhythm. This study examined the safety and efficacy of vernakalant in converting atrial flutter (AFL) to sinus rhythm.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Cardiostim Editorial

              A Camm (2010)
                Bookmark

                Author and article information

                Contributors
                Richard.Folkeringa@znb.nl
                Journal
                Neth Heart J
                Neth Heart J
                Netherlands Heart Journal
                Bohn Stafleu van Loghum (Houten )
                1568-5888
                1876-6250
                4 March 2014
                4 March 2014
                June 2014
                : 22
                : 6
                : 297-300
                Affiliations
                [ ]Department of Cardiology, Medical Centre Leeuwarden, Henry Dunantweg 2, 8934 AD Leeuwarden, the Netherlands
                [ ]Thrombosis service Friesland Noord, Borniastraat 34, 8934 AD Leeuwarden, the Netherlands
                [ ]Department of Internal Medicine, Medical Centre Leeuwarden, Henry Dunantweg 2, 8934 AD Leeuwarden, the Netherlands
                [ ]Department of Pharmacy, Medical Centre Leeuwarden, Henry Dunantweg 2, 8934 AD Leeuwarden, the Netherlands
                Article
                529
                10.1007/s12471-014-0529-9
                4031353
                24590768
                cc00238a-606b-4704-8c9e-e5661b01d534
                © The Author(s) 2014

                Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

                History
                Categories
                Short Communication
                Custom metadata
                © The Author(s) 2014

                Cardiovascular Medicine
                atrial fibrillation,novel oral anticoagulants,anticoagulation
                Cardiovascular Medicine
                atrial fibrillation, novel oral anticoagulants, anticoagulation

                Comments

                Comment on this article